14
NEWS
SGLT2s & diabetic foot disease
People with a history of foot ulcers
or amputations should be prescribed
SGLT2 inhibitors, according to
new research led by a team from
Leicester.
Professor Kamlesh Khunti, Dr
Patrick Highton and a team of experts
have identified a general clinical
confidence in prescribing SGLT2
inhibitors to people with diabetesrelated
foot disease, so long as they
do not have an active ulcer and the
drug canagliflozin is not prescribed.
In addition, the study has outlined
that SGLT2 inhibitors should be
prescribed to people with Type
2 diabetes with concurrent heart
failure and/or chronic kidney disease,
regardless of ulceration status.
Healthcare practitioners from a
range of relevant clinical backgrounds
were asked to rate their agreement
with various statements related
to prescribing SGLT2 inhibitors
in people with diabetic foot ulcer
disease.
Lead author Dr Highton, Research
Fellow for the NIHR ARC East
Midlands, said: "Through this study,
we have been able to capture the
views of clinicians working across
diabetes care and understand their
attitudes toward prescribing SGLT2
inhibitors in people with diabetic
foot disease. Given the complexities
involved in managing diabetic
foot complications, it is vital that
treatment decisions are informed
by both clinical experience and
consensus-based recommendations."
Kaleido accelerates scale
ViCentra has announced that it has
closed an upsized Series D financing
round having secured some $85m.
New investor Innovation
Industries led the round with
matching participation from existing
investors Partners in Equity and
Invest-NL. EQT Life Sciences and
Health Innovations also provided
continued funding support.
The Netherlands-based ViCentra
plans to use the funds to accelerate
manufacturing scale, launch its nextgeneration
Kaleido 2 insulin patch
pump in Europe and prepare for US
market entry.
Kaleido, described by the
company as the smallest, lightest and
most precise insulin patch pump in
its class, offers premium materials
and customizable aluminium shells
in 10 colour options to deliver the
feel of personal technology rather
than a traditional medical device.
It integrates with Diabeloop's selflearning
automated insulin delivery
algorithm and Dexcom's leading
continuous glucose monitors. The
pump offers users options in terms
of wearability and comes with
two durable, rechargeable pumps,
eliminating the need to dispose of
the pump every three days. Users
can choose between a short tube for
placement as a patch directly on the
body or a longer tube for carrying
the pump in the pocket. They can
also pause or take the pump off for
intermittent breaks.
Tom Arnold, CEO at ViCentra
commented, "With this funding, we
can meet surging European demand
and accelerate our entry into the
US market. This is a pivotal moment
for both the company and the
community we serve."